NCT05376904

A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Local Administration of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 86 (actual)
• Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy, and safety of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy. To explore the reasonable dosage of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy.

Conditions

• Postsurgical Pain Management

Interventions

Type	Name	Description
DRUG	HR18034	HR18034 low dose
DRUG	HR18034	HR18034 midium dose
DRUG	HR18034	HR18034 high dose
DRUG	ropivacaine HCl.	ropivacaine HCl.

Timeline

• Start date: 2022-06-13
• Primary completion: 2022-10-05
• Completion: 2022-10-05
• First posted: 2022-05-17
• Last updated: 2023-03-20

Locations

18 sites across 1 country: China